67 related articles for article (PubMed ID: 21050557)
1. [Efficacy and safety of natalizumab for multiple sclerosis and Crohn's disease: a meta analysis].
Li YY; Li YP; Sun X; Wang L; Wen J; Cheng L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Oct; 32(5):533-42. PubMed ID: 21050557
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
Keeley KA; Rivey MP; Allington DR
Ann Pharmacother; 2005 Nov; 39(11):1833-43. PubMed ID: 16219898
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
Ko HH; Bressler B
Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis.
Chandar AK; Singh S; Murad MH; Peyrin-Biroulet L; Loftus EV
Inflamm Bowel Dis; 2015 Jul; 21(7):1695-708. PubMed ID: 25856769
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab for active Crohn's disease.
Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
[TBL] [Abstract][Full Text] [Related]
6. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of natalizumab for formulary consideration.
Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT
Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease.
Lin Z; Bai Y; Zheng P
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1100-10. PubMed ID: 21971373
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
[TBL] [Abstract][Full Text] [Related]
10. [Natalizumab in the treatment of multiple sclerosis].
Horga A; Horga de la Parte JF
Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis: serious adverse events in Crohn's disease patients treated with TNF-alpha inhibitors.
Zhang D; Xiong B; Li X; Xu T; Yu M
Hepatogastroenterology; 2013 Sep; 60(126):1333-42. PubMed ID: 23340167
[TBL] [Abstract][Full Text] [Related]
13. [Meta-analysis of Shenmai injection treatment for acute myocardial infarction].
Hu J; Zhang W; Xie YM; Wang LX; Nie XL; Zhang YL
Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2760-7. PubMed ID: 23285929
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of interferon-gamma-targeted therapy in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials.
Cui D; Huang G; Yang D; Huang B; An B
Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):507-13. PubMed ID: 23433962
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab: bench to bedside and beyond.
Rudick R; Polman C; Clifford D; Miller D; Steinman L
JAMA Neurol; 2013 Feb; 70(2):172-82. PubMed ID: 23128399
[TBL] [Abstract][Full Text] [Related]
16. Clinical adverse effects of natalizumab: Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails.
Li H; Shi FH; Huang SY; Zhang SG; Gu ZC; Wei JF
Medicine (Baltimore); 2018 Jul; 97(28):e11507. PubMed ID: 29995817
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals.
Juillerat P; Wasan SK; Fowler SA; Friedman S; Pabby VK; Coukas JA; Barto AE; Pellish R; Germansky KA; Cheifetz AS; Korzenik JR; Farraye FA; Yajnik V
Inflamm Bowel Dis; 2013 Oct; 19(11):2457-63. PubMed ID: 23962896
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis.
Nikfar S; Rahimi R; Rezaie A; Abdollahi M
Arch Med Sci; 2010 Apr; 6(2):236-44. PubMed ID: 22371753
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab: overview of its pharmacology and safety.
Baker DE
Rev Gastroenterol Disord; 2007; 7(1):38-46. PubMed ID: 17392628
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab in the treatment of pediatric multiple sclerosis.
Talab R; Talabova M; Klzo L
Neuro Endocrinol Lett; 2012; 33(6):579-89. PubMed ID: 23160229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
